PT-141
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers.
PT-141 is Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers. Whether it is appropriate depends on your medical history, goals, current medications, and testing — evaluated by a licensed VidaVital Medical provider during a live consultation. Educational content only; not medical advice.
- PT-141 is sometimes discussed off-label.
- Your provider determines whether testing is needed.
- Providers may evaluate it in sexual-wellness.
- A licensed VidaVital provider must complete a live consultation before any treatment is prescribed.
What is it?
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers. A licensed provider reviews suitability, monitoring, and any needed testing during a live consultation.
What may it support?
- Sexual desire research
- Erectile response research
Where might it fit?
Bloodwork & monitoring
Potential side effects
- Injection-site reaction
- Mild GI discomfort
- Rare allergic reaction
Who may not be a candidate?
- • Uncontrolled hypertension
- • Cardiovascular disease
Drug interactions
- • Providers review all medications during consultation
Regulatory disclosures
FDA-approved for hypoactive sexual desire disorder in premenopausal women; other uses are off-label.
Speak With a Licensed Medical Provider
If you're interested in learning whether peptide therapy may be appropriate for your health goals, schedule a consultation with a licensed VidaVital Medical provider. Your provider will review your medical history, discuss available treatment options, and determine whether any therapy is appropriate for your individual needs.
Frequently asked questions
Sources
- Provider-reviewed clinical summary — reviewed 2026-01-15 by VidaVital Medical